ReviewFrontiers in neurology2025
Prognostic and predictive determinants in high-grade gliomas: integrating tumor-intrinsic biology with patient and system-level factors.
Review in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Current Status and Evolution of Immunotherapy in Glioma Management.International journal of medical sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Adult-type high-grade gliomas (HGGs) represent a biologically heterogeneous and clinically aggressive class of primary central nervous system tumors, characterized by diffuse infiltration, therapeutic resistance, and poor prognosis. Contemporary advances in molecular neuro-oncology have redefined prognostic stratification, shifting from purely histopathological frameworks to integrated molecular classification. This narrative review critically examines the intrinsic biological determinants of prognosis in HGGs, as delineated in the 2021 World Health Organization Classification of Tumors of the Central Nervous System, which differentiates glioblastoma (IDH-wildtype), astrocytoma (IDH-mutant), and oligodendroglioma (IDH-mutant, 1p/19q-codeleted) based on distinct molecular signatures. We examine the prognostic and therapeutic relevance of canonical biomarkers, alongside emerging molecular alterations and autophagy-related gene expression. In addition, we explore the tumor microenvironment and immune landscape of HGGs, and highlight the growing role of radiogenomics and artificial intelligence in integrating imaging with multi-omics data for personalized risk stratification. Beyond tumor-intrinsic biology, increasing attention is being directed toward patient-level and system-level determinants that shape prognosis. This review also synthesizes current evidence on the impact of demographic, clinical, therapeutic, and socio-economic factors influencing survival in patients with HGGs. A multidimensional approach to prognostication that integrates molecular, clinical, and contextual data is therefore essential for both improving survival and advancing health equity. By synthesizing established and emerging prognostic insights, this review underscores the critical role of tumor-intrinsic biology in guiding precision oncology approaches and developing biologically informed prognostic frameworks for patients with HGGs, while supporting the integration of non-biological determinants into clinical frameworks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.